Market Overview

UPDATE: Jefferies Cuts PT to $15 on Rigel Pharmaceuticals on Disappointing Fostamatinib Results

Share:
Related RIGL
Why The Last Week Of 2016 Could Be Big For Biotech Catalysts
10 Stocks With Lowest Close In Three Weeks

Jefferies reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL) but lowered its price target from $21 to $15.

Jefferies noted, "RIGL announced OSKIRA-4 results in which fostamatinib monotherapy failed to show non-inferiority to Humira. In a separate analysis, higher dose regimens of fostamatinib showed superiority against placebo. With $3 in year-end cash and $2 in cash approval milestones if fostamatanib can be approved, we believe the selloff reflects an overly negative Street view on fostamatinib prospects and would be a buyer."

Rigel Pharmaceuticals closed at $8.43 on Wednesday.

Latest Ratings for RIGL

DateFirmActionFromTo
Sep 2016JefferiesMaintainsBuy
Aug 2016BMO CapitalMaintainsOutperform
Aug 2016BMO CapitalInitiates Coverage onOutperform

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (RIGL)

View Comments and Join the Discussion!